Skip to main
  1. Stocks
  2. ProQR Therapeutics
  3. Forecast
PRQR

ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics (PRQR) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProQR Therapeutics is attractive because its AX-0810 data already show clear dose-dependent target engagement, including up to an 8-fold rise in serum total bile acids, increased circulating TUDCA, and higher plasma conjugated bile acids, while maintaining a favorable safety profile with no SAEs to date. The investment case is strengthened by AX-0811, which management expects to deliver 40%–60% greater editing and longer dosing intervals, with preclinical data suggesting a 1.6-fold longer half-life, >4x greater potency in vivo, and meaningful reductions in hepatocyte, bile duct, and portal vein bile acid burden. Its focus on NTCP modulation is also biologically compelling because human NTCP deficiency appears benign, supporting a differentiated, disease-modifying approach in pediatric biliary atresia and other severe cholestatic diseases.

Bears say

ProQR Therapeutics is weighed down by high clinical and regulatory uncertainty, including safety concerns tied to serial RNA exposure, the risk that Phase Ib/II/III data disappoint, and the possibility that the EMA or FDA interpret results differently or limit approved indications. Its lead biliary atresia program also faces practical execution hurdles such as a narrow enrichment window, biomarker constraints, and a still-unproven regulatory path for surrogate endpoints, which makes clinical validation difficult. Fundamentally, the company remains in a cash-burning, early-development stage and may need additional debt or equity funding that could be dilutive, while facing intense competition from better-resourced RNA and gene-therapy rivals that could make its therapies non-competitive or obsolete.

ProQR Therapeutics (PRQR) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction

Get the latest ProQR Therapeutics (PRQR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ProQR Therapeutics (PRQR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProQR Therapeutics (PRQR) Forecast

Analysts have given ProQR Therapeutics (PRQR) a Strong Buy based on their latest research and market trends.

According to 5 analysts, ProQR Therapeutics (PRQR) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProQR Therapeutics (PRQR)


ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction

Get the latest ProQR Therapeutics (PRQR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ProQR Therapeutics (PRQR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PRQR stock data and trends